Traceability can be defined as complete visibility for your product distribution and supply chain. It’s like a unique fingerprint that identifies, verifies and follows individual products ─ after they leave the manufacturing plant, towards the end user. Through systematic, documented identification and recorded data, traceability allows you to verify and track the history, location, and even the state or status of an item, regardless of where it is in the supply chain. This ability can provide a number of unprecedented efficiency gains.
As business environments change and resources become harder or more expensive to obtain, developing innovative ways to stay competitive and ensure long-term success becomes increasingly important. New and disruptive technologies make this possible in ways that were previously unimaginable. Traceability in particular provides a wide range of benefits through:
TRUST AND AUTHENTICITY – Save time and money by building trust with both suppliers and customers, who rely on you to deliver authentic, high-quality products.
PERFORMANCE AND EFFICIENCY – Gain access to large amounts of actionable data that allows you to make better decisions and pinpoint potential losses.
SUSTAINABILITY AND SAVINGS – Get a real-time view of raw materials and maximize your resources.
Serving the pharma industry for nearly 30 years, OPTEL offers proven custom and preconfigured traceability solutions to help achieve serialization compliance and so much more.
OPTEL offers turnkey vision inspection and traceability solutions for medical devices, designed to meet current and future needs.
OPTEL enables healthcare providers in hospitals and retail pharmacies to achieve compliance requirements related to the verification and decommissioning of prescription medications
Achieve unprecedented transparency,
performance, and manufacturing efficiency thanks to the Intelligent Supply
Chain enabled by OPTEL’s end-to-end traceability systems, leveraging
blockchain technologies.
Increase global visibility in complex supply chains with OPTEL, by tracing raw materials from even the most remote production and extraction sites to the consumer, thanks to geo-tracking and cutting-edge technologies.
Now a Certified B Corporation, OPTEL is a leading multinational provider of traceability systems, and its mission is to use its innovative technologies to create a better world through responsible capitalism. The company’s renowned solutions ensure the quality of consumer health products and help stop counterfeiting of pharmaceuticals and medical devices throughout the world. OPTEL is also adapting its technologies to create efficiencies in various other sectors ─ from health-related industries to smart manufacturing and more, all can benefit from global traceability. OPTEL’s expertise will allow diverse industries to measure, inspect, control and track a variety of elements to improve quality and make better use of resources.
OPTEL GROUP is pleased to announce that the AI-Powered Supply Chain Consortium it is part of was named one of the five official winners of the Innovation Supercluster Initiative led by the Government of Canada. OPTEL’s traceability technologies and vision are an integral part of the consortium project as it is this combination that will enable the intelligent supply chains required to create a sustainable economy.
OPTEL GROUP, a leading global provider of traceability systems for diverse industries ─ namely, pharmaceuticals and medical devices ─ is pleased to announce that it is expanding its traceability offering even further through the acquisition of GeoTraceability.
OPTEL GROUP, a leading global provider of traceability systems for the pharmaceutical and medical device industries, announced today that it is expanding its traceability offering through the acquisition of Verify Brand.
On June 20, 2018, ANVISA published Resolution RDC232, which states that all labels for coronary artery stents, pharmacological stents for coronary arteries, and implants for knee or hip arthroplasty must now include traceability barcodes.
On June 30, the FDA announced that it is now allowing additional time for pharmaceutical manufacturers to comply with product identifier requirements.